Issue Date: April 23, 2012
Three Deals Signed For Pharmaceutical Chemicals
Last week saw a run of contract manufacturing deals in the pharmaceutical sector. Albany Molecular Research Inc. was selected by Biota Holdings, an anti-infectives drug company in Australia, to develop and manufacture laninamivir, an influenza antiviral. Biota is seeking to establish U.S. manufacturing of laninamivir, a second-generation neuraminidase inhibitor, to facilitate clinical trials in support of a New Drug Application with FDA. Meanwhile, Germany’s Agennix has contracted with Lonza . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society